Advanced search
Publication Cover
Platelets Volume 31, 2020 - Issue 7
Submit an article Journal homepage
134
Views
2
CrossRef citations to date
0
Altmetric
Article commentary

Aspirin after PCI: in the twilight of its years?

William A. E. Parker1 Cardiovascular Research Unit, University of Sheffield, Sheffield, UK;2 South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7822-8852
ORCID Icon
Pages 831-833 | Received 01 Jul 2020, Accepted 06 Jul 2020, Published online: 15 Jul 2020

References

  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al.ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-477.
  • Zwart B, Yazdani M, Ow KW, Richardson JD, Iqbal J, Gunn JP, Storey RF. Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets 2020;31:174-178.
  • Parker WA, Storey RF. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart 2016;102:783–789. DOI:10.1136/heartjnl-2015-307858
  • Storey RF, Parker WAE. Choices for potent platelet inhibition in patients with diabetes mellitus. Circulation 2016;134:793–796. DOI:10.1161/CIRCULATIONAHA.116.023835
  • Iantorno M, Lipinski MJ, Garcia-Garcia HM, Forrestal BJ, Rogers T, Gajanana D, Buchanan KD, Torguson R, Weintraub WS, Waksman R. Meta-analysis of the impact of strut thickness on outcomes in patients with drug-eluting stents in a coronary artery. Am J Cardiol 2018;122:1652–1660. DOI:10.1016/j.amjcard.2018.07.040
  • Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, Lassila R, Storey RF, Sorbets E, et al. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention 2015;11:737-745.
  • Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381:2032–2042. DOI:10.1056/NEJMoa1908419
  • Baber U, Zafar MU, Dangas G, Escolar G, Angiolillo DJ, Sharma SK, Kini AS, Sartori S, Joyce L, Vogel B, et al. Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy. J Am Coll Cardiol 2020;75:578–586. DOI:10.1016/j.jacc.2019.11.056
  • Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011;9:552–561. DOI:10.1111/j.1538-7836.2010.04160.x
  • Leadbeater PDM, Kirkby NS, Thomas S, Dhanji AR, Tucker AT, Milne GL, Mitchell JA, Warner TD. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost 2011;9:2050–2056. DOI:10.1111/j.1538-7836.2011.04450.x
  • Scavone M, Femia EA, Caroppo V, Cattaneo M. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2. Eur Heart J 2016;37:3347–3356. DOI:10.1093/eurheartj/ehv551
  • Parker WAE, Thorneycroft K, Judge HM, Storey RF. Additive effects of aspirin and potent P2Y12 inhibition on platelet macro- and microaggregation of relevance to acute thrombotic stroke, ESC Heart Stroke 2020, Barcelona, Spain.
  • Teng R, Maya J, Butler K. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets 2013;24:615–624. DOI:10.3109/09537104.2012.748185
  • Parker WAE, Storey RF. Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets 2020;1–8. DOI:10.1080/09537104.2020.1714574
  • Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:1524–1534. DOI:10.1056/NEJMoa1908973
  • Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B, et al. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets 2019;30:148–157. DOI:10.1080/09537104.2019.1572880
  • Li J, Sheng Z, Tan Y, Liu C, Zhou P, Zhou J, Chen R, Chen Y, Song L, Zhao H, et al. Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. Platelets 2019;1–7. https://pubmed.ncbi.nlm.nih.gov/31645164/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.